Genta is building a portfolio of products targeted against some of the most deadly diseases and conditions facing patients with cancer today.   With four products in the pipeline and on-going clinical trials in all phases of development (Preclinical to Phase III), Genta is committed to better the lives of people with cancer.    

Genta’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules.  Genasense® (oblimersen sodium) Injection is the Company’s lead compound from its oligonecleotide program.  The leading drug candidate from the small molecule program is G4544.  This compound has the same active ingredient as Ganite (gallium nitrate) Injection, a product currently marketed by Genta.  G4544 represents the successful reformulation of the clinically active ingredient into a tablet formulation that can be taken by mouth for extended periods.  The IND proposes a dose-ranging trial of G4544 in normal volunteers that will examine safety and pharmacokinetics providing a rapid path to regulatory approval.

For more information on the Genta clinical development program please contact us at or 1-888-To-Genta (1-888-864-3682).